New report frames opioid prescribing guidelines for acute pain
A new report issued by the National Academies of Sciences, Engineering, and Medicine (NASEM) follows the patient-centered path in recommending that clinicians develop plans for addressing pain in patients based on the individual.
FDA tasked NASEM with developing the report in order for medical groups, health care providers, and others to evaluate current and future opioid prescribing to support a clinical practice guideline and to identify gaps in the evidence where future research is needed. The report is meant to serve as a framework on opioid prescribing guidelines for acute pain.
“One of the ways we believe we can work together with medical professional societies is by developing a framework that can assist them in creating and evaluating evidence-based guidelines on appropriate opioid analgesic prescribing to treat acute pain caused by specific medical conditions and common surgical procedures for which these drugs are prescribed,” said FDA in a statement.
FDA said it will consider recommendations included in the NASEM report, especially as the agency works to implement the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act (SUPPORT Act) provision that requires the development of evidence-based opioid prescribing guidelines for acute pain.
According to the NASEM report, specific areas to focus on include developing or modifying prescribing guidelines for C-sections, wisdom tooth removal, low back pain, sickle cell disease, and migraines.